Microbial (Pro)TGase

Bacterial Pro-transglutaminase


(Pro-BTG, recombinantly produced in E. coli,
gene derived from Streptomyces mobaraensis)

Order
Quantity
Price
Status
250 µg 270 € available


Documents
Art. No. T016
Synonym EC 2.3.2.13; Protein-glutamine-γ-glutamyltransferase
Molecular Weight 43 kDa
Source Recombinantly produced in E. coli
Purity > 90% [SDS-PAGE and Coomassie staining]
Activation 10 μl His6-rProTG (1 μg/μl)
35 μl 50 mM Tris-HCl pH 8
5 μl Dispase II (Roche) (0.2 μg/μl)
Incubate for 20 min at 30°C
Specific Activity 13 U/mg [One unit will catalyse the formation of 1 μmole of hydroxamate per min from Z-Gln-Gly-OH and hydroxylamine at pH 6.0 at 37°C, Grossowicz et al. (1950)]
Appearance White lyophilized solid
Reagents The Protransglutaminase is lyophilised from 10 mM Tris-HCl pH 8.0, 150 mM NaCl.
Reconstitution Add the desired volume H2O to the vial of lyophilized powder.
Application Labelling, immobilisation, conjugation and modification of proteins.
Storage Store at –20°C in working aliquots. Repeated freez ing and thawing is not recommended.
Delivery at ambient temperature is possible
Reference(s) Pasternack et al., Eur. J. Biochem. 1998, 257:570-6
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA